Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver Disease | Zendy

Sarah Kattakuzhy | Zendy; Eleanor Wilson | Zendy; Sreetha Sidharthan | Zendy; Zayani Sims | Zendy; Mary McLaughlin | Zendy; Angie Price | Zendy; Rachel Silk | Zendy; Chloe Gross | Zendy; Elizabeth Akoth | Zendy; Maryellen McManus | Zendy; Benjamin Emmanuel | Zendy; Shikha Shrivastava | Zendy; Lydia Tang | Zendy; Amy Nelson | Zendy; Gebeyehu Teferi | Zendy; José Chávez | Zendy; Brian Lam | Zendy; Hongmei Mo | Zendy; A. Osinusi | Zendy; Michael A. Polis | Zendy; Henry Masur | Zendy; Anita Kohli | Zendy; Shyamasundaran Kottilil | Zendy

Open Access

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver Disease

Author(s) -

Sarah Kattakuzhy,

Eleanor Wilson,

Sreetha Sidharthan,

Zayani Sims,

Mary McLaughlin,

Angie Price,

Rachel Silk,

Chloe Gross,

Elizabeth Akoth,

Maryellen McManus,

Benjamin Emmanuel,

Shikha Shrivastava,

Lydia Tang,

Amy Nelson,

Gebeyehu Teferi,

José Chávez,

Brian Lam,

Hongmei Mo,

A. Osinusi,

Michael A. Polis,

Henry Masur,

Anita Kohli,

Shyamasundaran Kottilil

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ897

Subject(s) - medicine , ledipasvir , sofosbuvir , regimen , hepatitis c virus , hepatitis c , gastroenterology , adverse effect , cirrhosis , liver disease , combination therapy , immunology , ribavirin , virus

Treatment of genotype 1 hepatitis C virus (HCV) infection with combination directly acting antivirals (DAA) for 8-24 weeks is associated with high rates of sustained virologic response (SVR). We previously demonstrated that adding a third DAA to ledipasvir and sofosbuvir (LDV/SOF) can result in high SVR rates in patients without cirrhosis. In this study, we investigated whether a similar regimen would yield equivalent rates of cure in patients with advanced liver fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research